A detailed history of Group One Trading, L.P. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 129,290 shares of AMLX stock, worth $523,624. This represents 0.02% of its overall portfolio holdings.

Number of Shares
129,290
Previous 289,281 55.31%
Holding current value
$523,624
Previous $549,000 23.86%
% of portfolio
0.02%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.65 - $3.24 $263,985 - $518,370
-159,991 Reduced 55.31%
129,290 $418,000
Q2 2024

Aug 14, 2024

BUY
$1.62 - $2.71 $107,825 - $180,374
66,559 Added 29.88%
289,281 $549,000
Q1 2024

May 10, 2024

SELL
$2.71 - $19.57 $761,374 - $5.5 Million
-280,950 Reduced 55.78%
222,722 $632,000
Q4 2023

Feb 14, 2024

BUY
$12.07 - $18.46 $5.63 Million - $8.61 Million
466,301 Added 1247.76%
503,672 $7.41 Million
Q3 2023

Nov 09, 2023

BUY
$18.08 - $23.45 $641,641 - $832,217
35,489 Added 1885.71%
37,371 $684,000
Q2 2023

Aug 09, 2023

SELL
$20.98 - $31.42 $36,085 - $54,042
-1,720 Reduced 47.75%
1,882 $40,000
Q1 2023

May 12, 2023

SELL
$27.71 - $40.93 $607,846 - $897,840
-21,936 Reduced 85.9%
3,602 $105,000
Q4 2022

Feb 09, 2023

SELL
$29.75 - $39.26 $1.89 Million - $2.49 Million
-63,447 Reduced 71.3%
25,538 $943,000
Q3 2022

Nov 09, 2022

SELL
$17.15 - $30.92 $1.14 Million - $2.05 Million
-66,403 Reduced 42.73%
88,985 $2.51 Million
Q2 2022

Aug 11, 2022

BUY
$6.85 - $19.93 $1.06 Million - $3.07 Million
154,145 Added 12401.05%
155,388 $2.99 Million
Q1 2022

May 12, 2022

BUY
$12.85 - $32.9 $15,972 - $40,894
1,243 New
1,243 $16,000

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $237M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.